GPR55: A Potential Drug Target for Various Diseases (G9290)

Target Name: GPR55

NCBI ID: G9290

GPR55

GPR55: A Potential Drug Target for Various Diseases

GPR55 (G protein-coupled receptor 55) is a G protein-coupled receptor that is expressed in various tissues and cells in the body. It is a member of the GPR55 family, which includes GPR51, GPR52, GPR53, GPR54, and GPR55. GPR55 is a potential drug target and has been identified as a biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic pain.

GPR55 is a transmembrane protein that is located at the end of the cell membrane. It consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the binding of GPR55 to its ligand, while the transmembrane domain is responsible for the transportation of the signaling molecule across the cell membrane. The intracellular domain is responsible for the interaction with the cell's intracellular signaling pathways.

GPR55 is a G protein-coupled receptor, which means that it is a protein that is composed of a guanoprotein that is covalently bound to a G protein. The G protein is a family of transmembrane proteins that plays a role in intracellular signaling. GPR55 is a member of the GPR55 family, which is characterized by its ability to activate intracellular signaling pathways.

GPR55 has been shown to play a role in various physiological processes in the body. For example, GPR55 has been shown to be involved in pain signaling. Studies have shown that GPR55 is involved in the transmission of pain signals from the body's tissues to the central nervous system. GPR55 has also been shown to be involved in the regulation of inflammation, as it has been shown to play a role in the production of pro-inflammatory cytokines.

In addition to its role in pain and inflammation, GPR55 has also been shown to be involved in the regulation of cellular processes that are important for maintaining tissue homeostasis. For example, GPR55 has been shown to play a role in the regulation of blood pressure, as it has been shown to increase the blood pressure in response to changes in blood volume or resistance.

GPR55 has also been shown to be involved in the regulation of body weight and metabolism. Studies have shown that GPR55 is involved in the regulation of appetite and metabolism, as it has been shown to play a role in the production of neuropeptides that regulate food intake and energy expenditure.

GPR55 has also been shown to be involved in the regulation of sleep and wakefulness. Studies have shown that GPR55 is involved in the regulation of sleep and wakefulness, as it has been shown to play a role in the production of hormones that regulate the circadian rhythm.

In conclusion, GPR55 is a G protein-coupled receptor that is involved in various physiological processes in the body. It has been shown to play a role in pain signaling, inflammation, blood pressure regulation, body weight and metabolism, and sleep and wakefulness. As a result, GPR55 is a potential drug target and could be useful for the development of new treatments for various diseases.

Protein Name: G Protein-coupled Receptor 55

Functions: May be involved in hyperalgesia associated with inflammatory and neuropathic pain (By similarity). Receptor for L-alpha-lysophosphatidylinositol (LPI). LPI induces Ca(2+) release from intracellular stores via the heterotrimeric G protein GNA13 and RHOA. Putative cannabinoid receptor. May play a role in bone physiology by regulating osteoclast number and function

The "GPR55 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR55 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets